Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma

Blood Reviews - Tập 29 - Trang 143-152 - 2015
Alberto Mussetti1,2, Anita Kumar3,4, Parastoo B. Dahi1,3, Miguel-Angel Perales1,3, Craig S. Sauter1,3
1Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
2Universita degli Studi di Milano, Milan, Italy
3Weill Cornell Medical College, New York, NY, USA
4Department of Medicine, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Tài liệu tham khảo

Gianni, 2003, Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen), Blood, 102, 749, 10.1182/blood-2002-08-2476 Dreyling, 2005, Blood, 105, 2677, 10.1182/blood-2004-10-3883 Romaguera, 2005, High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine, J Clin Oncol, 23, 7013, 10.1200/JCO.2005.01.1825 Delarue, 2013, CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte, Blood, 121, 48, 10.1182/blood-2011-09-370320 Geisler, 2012, Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+autologous stem-cell support: still very long survival but late relapses do occur, Br J Haematol, 158, 355, 10.1111/j.1365-2141.2012.09174.x Rummel, 2013, Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial, Lancet, 381, 1203, 10.1016/S0140-6736(12)61763-2 Fisher, 2006, Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma, J Clin Oncol, 24, 4867, 10.1200/JCO.2006.07.9665 Wang, 2013, Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma, N Engl J Med, 369, 507, 10.1056/NEJMoa1306220 Goy, 2013, Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study, J Clin Oncol, 31, 3688, 10.1200/JCO.2013.49.2835 Maris, 2004, Allogeneic hematopoietic cell transplantation after fludarabine and 2Gy total body irradiation for relapsed and refractory mantle cell lymphoma, Blood, 104, 3535, 10.1182/blood-2004-06-2275 Tam, 2009, Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma, Blood, 113, 4144, 10.1182/blood-2008-10-184200 Armand, 2008, Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome, Biol Blood Marrow Transplant, 14, 418, 10.1016/j.bbmt.2008.01.008 Robinson, 2008, Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma, J Clin Oncol, 26, 4473, 10.1200/JCO.2008.17.0001 Cook, 2010, Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for blood and marrow transplantation, Biol Blood Marrow Transplant, 16, 1419, 10.1016/j.bbmt.2010.04.006 Gayoso, 2011, Long-term results of fludarabine/melphalan as a reduced-intensity conditioning regimen in mantle cell lymphoma: the GELTAMO experience, Ther Adv Hematol, 2, 5, 10.1177/2040620710396752 Le Gouill, 2012, Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience, Ann Oncol, 23, 2695, 10.1093/annonc/mds054 Hamadani, 2013, Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research, Biol Blood Marrow Transplant, 19, 625, 10.1016/j.bbmt.2013.01.009 Fenske, 2014, Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality, J Clin Oncol, 32, 273, 10.1200/JCO.2013.49.2454 Dietrich, 2014, Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT), Ann Oncol, 25, 1053, 10.1093/annonc/mdu097 Sohn, 2000, Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL, Am J Hematol, 65, 75, 10.1002/1096-8652(200009)65:1<75::AID-AJH14>3.0.CO;2-L Corradini, 2007, Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome, Leukemia, 21, 2316, 10.1038/sj.leu.2404822 Russell, 2005, Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation, Bone Marrow Transplant, 36, 437, 10.1038/sj.bmt.1705074 Bloor, 2008, High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma, Biol Blood Marrow Transplant, 14, 50, 10.1016/j.bbmt.2007.04.013 Ram, 2011, Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation, Biol Blood Marrow Transplant, 17, 1537, 10.1016/j.bbmt.2011.03.010 Morris, 2004, Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma, Blood, 104, 3865, 10.1182/blood-2004-03-1105 Belch, 2006, A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150, Ann Oncol, 18, 116, 10.1093/annonc/mdl316 Wang, 2012, Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial, Lancet Oncol, 13, 716, 10.1016/S1470-2045(12)70200-0 Leonard, 2012, Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma, Blood, 119, 4597, 10.1182/blood-2011-10-388298 Dasmahapatra, 2011, Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo, Mol Cancer Ther, 10, 1686, 10.1158/1535-7163.MCT-10-1108 Gill, 2014, Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma, Ann Oncol, 25, 1391, 10.1093/annonc/mdu142 Kahl, 2014, A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL), Blood, 123, 3398, 10.1182/blood-2013-11-537555 Davids, 2013, The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients Forstpointner, 2006, Blood, 108, 4003, 10.1182/blood-2006-04-016725 Rodríguez, 2007, Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma, Leuk Lymphoma, 48, 2172, 10.1080/10428190701618268 Witzig, 2008, Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, Leuk Lymphoma, 49, 1074, 10.1080/10428190801993470 Rummel, 2005, Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma, J Clin Oncol, 23, 3383, 10.1200/JCO.2005.08.100 Visco, 2013, Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation, J Clin Oncol, 31, 1442, 10.1200/JCO.2012.45.9842 Pham, 2003, Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis, J Immunol, 171, 88, 10.4049/jimmunol.171.1.88 O'Connor, 2005, Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma, J Clin Oncol, 23, 676, 10.1200/JCO.2005.02.050 Goy, 2009, Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study, Ann Oncol, 20, 520, 10.1093/annonc/mdn656 Friedberg, 2011, The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma, Blood, 117, 2807, 10.1182/blood-2010-11-314708 Kouroukis, 2011, A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172), Leuk Lymphoma, 52, 394, 10.3109/10428194.2010.546015 Witzig, 2005, Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma, J Clin Oncol, 23, 5347, 10.1200/JCO.2005.13.466 Ansell, 2008, Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group, Cancer, 113, 508, 10.1002/cncr.23580 Hess, 2009, Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma, J Clin Oncol, 27, 3822, 10.1200/JCO.2008.20.7977 Ansell, 2011, Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study, Lancet Oncol, 12, 361, 10.1016/S1470-2045(11)70062-6 Zinzani, 2013, Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study, Ann Oncol, 24, 2892, 10.1093/annonc/mdt366 Buggy, 2012, Bruton tyrosine kinase (BTK) and its role in B-cell malignancy, Int Rev Immunol, 31, 119, 10.3109/08830185.2012.664797 Honigberg, 2010, The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy, Proc Natl Acad Sci U S A, 107, 13075, 10.1073/pnas.1004594107 Advani, 2013, Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies, J Clin Oncol, 31, 88, 10.1200/JCO.2012.42.7906 Khouri, 1998, Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma, J Clin Oncol, 16, 3803, 10.1200/JCO.1998.16.12.3803 Thieblemont, 2005, Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma, Cancer, 104, 1434, 10.1002/cncr.21313 Ritchie, 2007, The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma, Ann Hematol, 86, 101, 10.1007/s00277-006-0193-2 Lacasce, 2012, Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL database, Blood, 119, 2093, 10.1182/blood-2011-07-369629 Geisler, 2008, Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group, Blood, 112, 2687, 10.1182/blood-2008-03-147025 Freedman, 1998, High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission, J Clin Oncol, 16, 13, 10.1200/JCO.1998.16.1.13 Till, 2008, Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma, Leuk Lymphoma, 49, 1062, 10.1080/10428190801923725 Gopal, 2002, High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma, Blood, 99, 3158, 10.1182/blood.V99.9.3158 Sorror, 2005, Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT, Blood, 106, 2912, 10.1182/blood-2005-05-2004 Robinson, 2008, Identification of prognostic factors predicting the outcome of reduced intensity allogeneic stem cell transplantation in mantle cell lymphoma Robinson, 2013, The EBMT lymphoma working party-European mantle cell lymphoma network consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma: recommendations applying the Delphi procedure Khouri, 1999, Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy, Ann Oncol, 10, 1293, 10.1023/A:1008380527502 Berdeja, 2001, Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma, Biol Blood Marrow Transplant, 7, 561, 10.1016/S1083-8791(01)70016-X Rifkind, 2005, Allogeneic stem cell transplantation for mantle cell lymphoma — does it deserve a better look?, Leuk Lymphoma, 46, 217, 10.1080/10428190400015022 Ganti, 2005, Hematopoietic stem cell transplantation in mantle cell lymphoma, Ann Oncol, 16, 618, 10.1093/annonc/mdi107 Laudi, 2006, Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma, Am J Hematol, 81, 519, 10.1002/ajh.20646 Kasamon, 2005, Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma, Biol Blood Marrow Transplant, 11, 39, 10.1016/j.bbmt.2004.09.007 Rodriguez, 2006, Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma, Biol Blood Marrow Transplant, 12, 1326, 10.1016/j.bbmt.2006.08.035 Hamadani, 2009, Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-Hodgkin lymphomas, Biol Blood Marrow Transplant, 15, 547, 10.1016/j.bbmt.2009.01.010 Khouri, 1998, Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies, J Clin Oncol, 16, 2817, 10.1200/JCO.1998.16.8.2817 Urbano-Ispizua, 2013, Association of graft vs. host disease (GVHD) with a lower relapse/progression rate after allogeneic hematopoietic stem cell transplantation (HSCT) with reduced intensity conditioning in patients with follicular and mantle cell lymphoma: a CIBMTR analysis Grigg, 1999, Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma, Bone Marrow Transplant, 23, 107, 10.1038/sj.bmt.1701540 Wudhikarn, 2011, Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome, Biol Blood Marrow Transplant, 17, 1497, 10.1016/j.bbmt.2011.02.009 Sorror, 2012, Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index (HCT-CI) for HCT outcomes at US transplant centers: a center for international blood and marrow transplant research (CIBMTR) study Romaguera, 2010, Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyper CVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma, Br J Haematol, 150, 200 Geisler, 2008, Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group, Blood, 112, 2687, 10.1182/blood-2008-03-147025 Flinn, 2014, Randomized trial of bendamustine–rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study, Blood, 123, 2944, 10.1182/blood-2013-11-531327 Ferrero, 2013, Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network phase ii trial Rahal, 2014, Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma, Nat Med, 20, 87, 10.1038/nm.3435